Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

2.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional disease progression in children with inherited peripheral neuropathies: A prospective cohort study.

Journal of neuromuscular diseases·2026
Same author

Post-intensive care sequelae after severe bacterial infections in previously healthy children.

Molecular and cellular pediatrics·2026
Same author

Identification of prognostic biomarkers in a large cohort of patients with LGMD R2.

Journal of neurology·2026
Same author

Whole-Body Pattern of Muscle Degeneration and Progression in Sarcoglycanopathies.

Annals of clinical and translational neurology·2025
Same author

Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry.

Brain : a journal of neurology·2025
Same author

Expert Consensus on Genetic Diagnostic Approaches for Patients With Limb-Girdle Muscular Dystrophy.

Neurology·2025

Related Experiment Video

Updated: Feb 19, 2026

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

25.6K

[Spinal muscular atrophy : Time for newborn screening?]

K Vill1, A Blaschek2, U Schara3

  • 1Abteilung für Neuropädiatrie, Entwicklungsneurologie und Sozialpädiatrie, Zentrum für neuromuskuläre Erkrankungen und Neuroimmunologie im Kindesalter, LMU Zentrum - iSPZ Hauner, Kinderklinik und Kinderpoliklinik, Dr. von Haunersches Kinderspital der Universität München, Lindwurmstraße 4, 80337, München, Deutschland. Katharina.vill@med.uni-muenchen.de.

Der Nervenarzt
|November 5, 2017
PubMed
Summary

Spinal muscular atrophy (SMA) is a severe childhood neurodegenerative disease. Early detection and presymptomatic treatment are crucial for improving outcomes, with newborn screening being a key goal.

Keywords:
Clinical trialsDrug therapyMolecular geneticsPresymptomatic diagnosisWerdnig-Hoffmann disease

More Related Videos

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.7K
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.1K

Related Experiment Videos

Last Updated: Feb 19, 2026

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

25.6K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.7K
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.1K

Area of Science:

  • Pediatric Neurology
  • Genetics
  • Neurodegenerative Diseases

Background:

  • Spinal muscular atrophy (SMA) is the most common fatal childhood neurodegenerative disease.
  • Severe infantile SMA (type 1) accounts for 60% of cases, often leading to death within 18 months without intervention.
  • Recent advancements have progressed from theoretical concepts to clinical trials, resulting in the first approved pharmacological treatment for SMA.

Purpose of the Study:

  • To highlight the critical role of early detection in the success of new SMA therapies.
  • To emphasize the benefits of initiating treatment before symptom onset for improved patient outcomes.
  • To discuss the feasibility and importance of presymptomatic diagnosis through molecular genetic newborn screening.

Main Methods:

  • Review of current therapeutic approaches and clinical trial data for SMA.
  • Analysis of the impact of treatment timing on patient outcomes.
  • Evaluation of the technical and ethical considerations for implementing newborn screening for SMA.

Main Results:

  • Pharmacological treatment for SMA has been approved for the first time.
  • Early treatment initiation, ideally before symptom onset, significantly improves outcomes compared to delayed treatment.
  • Presymptomatic diagnosis is essential to initiate treatment before irreversible motor neuron degeneration.

Conclusions:

  • Early detection is paramount for effective SMA therapy.
  • Initiating treatment prior to symptom onset offers the best chance for improved outcomes.
  • Molecular genetic newborn screening presents a viable strategy for achieving presymptomatic diagnosis and timely intervention in SMA.